The Center for Immunology and Biopreparations of Holguín (Cibho) is getting ready to start the clinical trial of CBA-100, a natural product elaborated by two Holguín scientists committed to counteracting the consequences of SARS-CoV- 2.

The protection of endemic species of flora in the mountainous area of the province of Holguín is one of the objectives of specialists at the Ministry of Science and Technology and Environment in the eastern territory.

After receiving the authorization of the Center for State Control of Medicines, Equipment and Medical Devices (Cecmed) and the approval of the Ministry of Public Health, a phase II-III clinical trial began at the Institute of Hematology and Immunology, aimed at evaluating the safety, immunogenicity and efficacy of a new version of the Cuban anti-pneumococcal vaccine Quimio-Vio, in adults from 50 to 74 years of age.